New TB vaccines show limited effectiveness in clinical trial

Tuberculosis (TB) remains a major global health challenge, causing millions of cases and deaths every year.

Scientists have long sought an improved vaccine to replace or supplement the century-old BCG vaccine, which works well for children but offers limited protection for adults.

A significant recent study, the PreVenTB trial, examined two new vaccine candidates, VPM1002 and Immuvac.

While these vaccines were proven safe, they unfortunately did not show significant protection against standard pulmonary TB in the general population.

However, the study provided some encouraging news: VPM1002 showed success in preventing extrapulmonary TB, and preliminary data suggests it might be particularly effective in children aged 6 to 14.

Interestingly, the researchers found that nutrition plays a key role, as vaccine effectiveness was lower in individuals who were underweight.

Moving forward, experts suggest that instead of a universal vaccine, we may need a stratified approach, combining vaccination with nutritional support and targeting specific age groups or high-risk demographics.

While these results are a reminder of the complexity of TB research, the global effort to end this disease continues with other promising candidates currently in development.